Lv2
170 积分 2024-05-13 加入
Stakeholders of Theranostics
21小时前
求助中
Stakeholders of Theranostics
14天前
已关闭
Is211At Really Happening?
1个月前
已完结
Theranostics and Patient-Specific Dosimetry
1个月前
已完结
Theranostics and Patient-Specific Dosimetry
1个月前
已关闭
Efficacy and Safety of Radiation Segmentectomy with 90Y Resin Microspheres for Hepatocellular Carcinoma
5个月前
已完结
Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
6个月前
已完结
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
6个月前
已完结
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
6个月前
已完结
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches
6个月前
已完结
皖公网安备34019202002308
